Proactive Investors - Run By Investors For Investors

Admedus in trading halt pending update on Admedus Immunotherapies transaction

Hong Kong investor Sun Bright Holdings is contributing up to $18 million for cancer vaccine and immunotherapies development
Admedus in trading halt pending update on Admedus Immunotherapies transaction
The securities will remain in trading halt until Wednesday, April 17, 2019, or when an announcement is made.

Admedus Ltd (ASX:AHZ) has been granted a trading halt by the ASX with an announcement pending in regards to the Admedus Immunotherapies sale transaction.

The trading halt will remain in place until the beginning of trading on April 17, 2019, or when an announcement is made to the market.

Admedus securities last traded at 6 cents.

READ: Admedus to spin-off immunotherapies business; shares surge

Last week the company made further progress towards securing up to $18 million in funding for its immunotherapies business, Admedus Vaccines Pty Ltd.

The company entered into a share sale agreement with Constellation Therapeutics and other shareholders of Admedus Vaccines whereby Constellation would acquire all the shares of Admedus Vaccines.

On completion of the transaction:

  • Admedus Vaccines will be a wholly-owned subsidiary of Constellation;

  • The company will hold a 29.13% interest in Constellation through AIPL;

  • Other shareholders will hold a 10.8% stake in Constellation;

  • Sun Bright Holding will hold a 60% interest in Constellation;

  • Sun Bright will contribute up to $18 million to Admedus Vaccines over the period to November 2022 to meet ongoing funding requirements; and

  • Admedus chief executive Wayne Paterson will be appointed as the chairman of Constellation and Professor Ian Frazer will be appointed as a consultant to oversee the vaccine and immunotherapies development.

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
Callitas CEO James Thompson
July 21 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use